Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04413201
Title AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Michael Hopp
Indications

lung non-small cell carcinoma

Therapies

Afatinib + Osimertinib

Osimertinib

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.